INT201955

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 2006
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 18
Total Number 19
Disease Relevance 11.91
Pain Relevance 1.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (DPP4) extracellular region (DPP4) cell adhesion (DPP4)
Golgi apparatus (DPP4) endoplasmic reticulum (DPP4) plasma membrane (DPP4)
Anatomy Link Frequency
fibroblasts 4
monocytes 3
Leukocyte 1
immune system 1
body 1
DPP4 (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 102 100.00 Very High Very High Very High
Inflammation 44 100.00 Very High Very High Very High
chemokine 75 97.64 Very High Very High Very High
antagonist 8 95.64 Very High Very High Very High
agonist 36 79.92 Quite High
rheumatoid arthritis 49 60.56 Quite High
spinal inflammation 38 60.24 Quite High
Arthritis 89 59.92 Quite High
bradykinin 10 59.04 Quite High
metalloproteinase 8 58.56 Quite High
Disease Link Frequency Relevance Heat
INFLAMMATION 44 100.00 Very High Very High Very High
Adhesions 21 100.00 Very High Very High Very High
Muscular Dystrophy 14 100.00 Very High Very High Very High
Arthropathy 6 100.00 Very High Very High Very High
Carcinoma 12 99.92 Very High Very High Very High
Choroideremia 1162 99.52 Very High Very High Very High
Body Weight 21 99.40 Very High Very High Very High
Cancer 274 99.04 Very High Very High Very High
Renal Cancer 156 97.92 Very High Very High Very High
Cough 37 95.80 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
However, such as in activity assays, a decreasing trend of mRNA levels was also observed for DPP IV in RO and for NEP in CCRCC and RO.
Regulation (trend) of DPP IV
1) Confidence 0.45 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2876082 Disease Relevance 0.60 Pain Relevance 0
However, there is a considerable risk of potential adverse effects of DPP-4 inhibitors, especially on the immune system.
Regulation (effects) of DPP-4 in immune system
2) Confidence 0.44 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.65 Pain Relevance 0
Figures 1.3.1 and 2.3.1 show the effects of DPP-4 inhibition on body weight.
Regulation (effects) of DPP-4 in body associated with body weight
3) Confidence 0.44 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.78 Pain Relevance 0.06
These effects of DPP IV inhibition on airway and other organ symptoms were predictable given the relationships between ACEI and cough, neutral endopeptidase (NEP, CD10; EC 3.24.11) with neurogenic inflammation, and complement C1 esterase inhibitor and hereditary angioneurotic edema [24,25].
Regulation (effects) of DPP IV associated with hereditary angioedema, inflammation, cough and neurogenic inflammation
4) Confidence 0.42 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2877018 Disease Relevance 0.47 Pain Relevance 0.20
Changes were not significant for DPP IV (Figure 3A) nor NEP expression (Figure 3B) in CCRCC and RO tumors when compared with their corresponding normal tissues.
Neg (not) Regulation (significant) of DPP IV associated with cancer
5) Confidence 0.39 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2876082 Disease Relevance 0.65 Pain Relevance 0
In addition, AACE/ACE recommends the use of DPP-4 inhibitors vs other oral agents in patients when HbA1c is in the range of 6.5%–7.5% and FPG and PPG levels are elevated.1



Regulation (use) of DPP-4
6) Confidence 0.35 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.12 Pain Relevance 0
Guidelines set forth by the AACE/ACE recognize the value of DPP-4 inhibitors, noting that they reduce both FPG and PPG and may be used in combination with metformin.
Regulation (value) of DPP-4
7) Confidence 0.35 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.26 Pain Relevance 0
Furthermore, DPP-4 has multiple substrates (all peptides with a penultimate alanine or proline in the N-terminal position); the physiological effect of DPP-4 inhibition on all substrates has not been characterised in full detail as yet.
Regulation (effect) of DPP-4
8) Confidence 0.34 Published 2010 Journal Pediatr Nephrol Section Body Doc Link PMC2874027 Disease Relevance 0.29 Pain Relevance 0.14
Values for the soluble DPP IV activities in CCRCC and in RO did not vary significantly.
Regulation (Values) of DPP IV
9) Confidence 0.27 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2876082 Disease Relevance 0.78 Pain Relevance 0
Moreover, the present manuscript shows that the modifications affecting DPP IV and NEP profiles along the different phenotypes of renal cancer are similar to those we observed in our previous studies on other membrane-bound peptidases, such as IRAP, APN and APA [12,13,28], and thus reinforces the idea that loss of several physiologically significant glycopeptidases may be a critical step in the etiogenesis of renal tumors.
Regulation (affecting) of DPP IV associated with renal cancer
10) Confidence 0.24 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2876082 Disease Relevance 0.91 Pain Relevance 0.03
did not significantly affect membrane-bound activity of DPP IV on fibroblasts (Figure 10b,c).
Neg (not) Regulation (affect) of DPP IV in fibroblasts
11) Confidence 0.20 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1779382 Disease Relevance 0.35 Pain Relevance 0.21
Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies

Leukocyte infiltration during acute and chronic inflammation is regulated by exogenous and endogenous factors, including cytokines, chemokines and proteases.

Regulation (regulated) of CD26 in Leukocyte associated with chemokine, inflammation, arthropathy and cytokine
12) Confidence 0.09 Published 2006 Journal Arthritis Res Ther Section Title Doc Link PMC1779382 Disease Relevance 0.58 Pain Relevance 0.42
Functional categories affected in both fibroblasts and monocytes of CHM patients included a large group of genes involved in regulation of cell adhesion and motility (NCAM-2, FMN1, ANKRD28, CSF3R, DMD, MLLT4, DPP4, TSPAN5, CD114, DMD, CYFIP2, WNT5A, MMP7), immune response (IL1, CC2, CFI, ELOVL2), regulation of trafficking and exocytosis (RGS11, SYT 6, GBF1) and transcriptional regulation (HOXD11, MRO, NRG1, NLRC3, NR2F6, SALL1, DIP2A, RSOPO2) (Fig. 7A).
Regulation (regulation) of DPP4 in monocytes associated with muscular dystrophy, choroideremia and adhesions
13) Confidence 0.06 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2793004 Disease Relevance 0.80 Pain Relevance 0.03
Functional categories affected in both fibroblasts and monocytes of CHM patients included a large group of genes involved in regulation of cell adhesion and motility (NCAM-2, FMN1, ANKRD28, CSF3R, DMD, MLLT4, DPP4, TSPAN5, CD114, DMD, CYFIP2, WNT5A, MMP7), immune response (IL1, CC2, CFI, ELOVL2), regulation of trafficking and exocytosis (RGS11, SYT 6, GBF1) and transcriptional regulation (HOXD11, MRO, NRG1, NLRC3, NR2F6, SALL1, DIP2A, RSOPO2) (Fig. 7A).
Regulation (regulation) of DPP4 in monocytes associated with muscular dystrophy, choroideremia and adhesions
14) Confidence 0.06 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2793004 Disease Relevance 0.80 Pain Relevance 0
Functional categories affected in both fibroblasts and monocytes of CHM patients included a large group of genes involved in regulation of cell adhesion and motility (NCAM-2, FMN1, ANKRD28, CSF3R, DMD, MLLT4, DPP4, TSPAN5, CD114, DMD, CYFIP2, WNT5A, MMP7), immune response (IL1, CC2, CFI, ELOVL2), regulation of trafficking and exocytosis (RGS11, SYT 6, GBF1) and transcriptional regulation (HOXD11, MRO, NRG1, NLRC3, NR2F6, SALL1, DIP2A, RSOPO2) (Fig. 7A).
Regulation (regulation) of DPP4 in monocytes associated with muscular dystrophy, choroideremia and adhesions
15) Confidence 0.06 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2793004 Disease Relevance 0.79 Pain Relevance 0
Interestingly, expression levels of genes encoding secreted proteins from different functional groups including CFI, CC2, NRG1, MMP7, WNT5A, RSOPO2, CSF3R, DPP4, IL1 were deregulated altered in CHM cells compared to the control.
Regulation (deregulated) of DPP4 associated with choroideremia
16) Confidence 0.03 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2793004 Disease Relevance 0.69 Pain Relevance 0.07
Functional categories affected in both fibroblasts and monocytes of CHM patients included a large group of genes involved in regulation of cell adhesion and motility (NCAM-2, FMN1, ANKRD28, CSF3R, DMD, MLLT4, DPP4, TSPAN5, CD114, DMD, CYFIP2, WNT5A, MMP7), immune response (IL1, CC2, CFI, ELOVL2), regulation of trafficking and exocytosis (RGS11, SYT 6, GBF1) and transcriptional regulation (HOXD11, MRO, NRG1, NLRC3, NR2F6, SALL1, DIP2A, RSOPO2) (Fig. 7A).
Regulation (regulation) of DPP4 in fibroblasts associated with muscular dystrophy, choroideremia and adhesions
17) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2793004 Disease Relevance 0.80 Pain Relevance 0
Functional categories affected in both fibroblasts and monocytes of CHM patients included a large group of genes involved in regulation of cell adhesion and motility (NCAM-2, FMN1, ANKRD28, CSF3R, DMD, MLLT4, DPP4, TSPAN5, CD114, DMD, CYFIP2, WNT5A, MMP7), immune response (IL1, CC2, CFI, ELOVL2), regulation of trafficking and exocytosis (RGS11, SYT 6, GBF1) and transcriptional regulation (HOXD11, MRO, NRG1, NLRC3, NR2F6, SALL1, DIP2A, RSOPO2) (Fig. 7A).
Regulation (regulation) of DPP4 in fibroblasts associated with muscular dystrophy, choroideremia and adhesions
18) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2793004 Disease Relevance 0.80 Pain Relevance 0.03
Functional categories affected in both fibroblasts and monocytes of CHM patients included a large group of genes involved in regulation of cell adhesion and motility (NCAM-2, FMN1, ANKRD28, CSF3R, DMD, MLLT4, DPP4, TSPAN5, CD114, DMD, CYFIP2, WNT5A, MMP7), immune response (IL1, CC2, CFI, ELOVL2), regulation of trafficking and exocytosis (RGS11, SYT 6, GBF1) and transcriptional regulation (HOXD11, MRO, NRG1, NLRC3, NR2F6, SALL1, DIP2A, RSOPO2) (Fig. 7A).
Regulation (regulation) of DPP4 in fibroblasts associated with muscular dystrophy, choroideremia and adhesions
19) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2793004 Disease Relevance 0.79 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox